Group 1 - The company received a notification from the Shenzhen Stock Exchange on January 23, 2026, regarding the acceptance of its application for issuing convertible bonds to unspecified objects [1] - The Shenzhen Stock Exchange has verified that the application documents for the issuance of convertible bonds are complete and has decided to accept the application [1] - The issuance of convertible bonds is subject to approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission, with uncertainties regarding the approval process and timeline [1]

Core Viewpoint - The company is actively progressing with its innovative drugs QHRD106 and QHRD107, addressing investor concerns regarding delays in clinical trials [2]. Group 1 - The company responded to investor inquiries about potential major issues causing delays in the clinical trial applications for its innovative drugs [2]. - Both QHRD106 and QHRD107 are currently advancing in their clinical trial processes in an orderly manner [2]. - The company is committed to following the requirements set by the Center for Drug Evaluation (CDE) to ensure the new drug development process is fully supported [2].

证券代码：002550 证券简称：千红制药 公告编号：2025-043 常州千红生化制药股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更以往股东会已通过的决议的情形。 一、会议召开情况 （一）召开时间： 1、现场会议召开时间：2025 年 12 月 10 日（周三）下午 14:30 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 12 月 10 日 9:15-9:25，9:30-11:30，13:00-15:00。 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 12 月 10 日 9:15 至 15:00 的任意时间。 （二）召开地点：公司云河路厂区行政楼二楼会议室（江苏省常州市新北区 云河路 518 号） （三）召开方式：现场表决与网络投票相结合 （四）召集人：公司董事会 （五）主持人：公司董事长王耀方先生 2、网络投票时间：2025 年 12 月 10 日 （六）本次股东会的召集、召开程序符合《公 ...

南京市鼓楼区集庆门大街 270 号苏宁环球国际中心 43 层 电话：025-85803866 传真：025-85803680 邮编：210003 北京国枫（南京）律师事务所 关于常州千红生化制药股份有限公司 2025 年第二次临时股东会的 法律意见书 国枫律股字[2025]H0052 号 致：常州千红生化制药股份有限公司（贵公司） 北京国枫（南京）律师事务所（以下简称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2025 年第二次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称 "《股东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证 券法律业务管理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简 称"《证券法律业务执业规则》"）等相关法律、行政法规、规章、规范性文件及《常 州千红生化制药股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会 议的召集与召开程序、召集人资格、出席会议人员资格、会议表决程序及表决结果等事 ...

Core Viewpoint - QHRD106 and QHRD107, the innovative drug projects of Qianhong Pharmaceutical, are currently advancing in clinical research in an orderly manner [1] Group 1 - The company is actively engaged in the clinical research phase for its innovative drug projects [1]

Group 1 - The article highlights a series of corruption cases involving pharmaceutical companies and agents bribing hospital personnel, with the National Healthcare Security Administration (NHSA) stating that such bribery disrupts normal medical practices and shifts sales from clinical value to high rebates and kickbacks [2][6] - Multiple companies, including Medtronic and A-share listed companies like Qianhong Pharmaceutical and Dezhan Health, have been named in recent court rulings related to these corruption cases [2][5] - Specific cases include Medtronic's agents bribing hospital officials with kickbacks of 5,000 yuan per stent and varying amounts for balloons, leading to a total bribe exceeding 14 million yuan [3][4] Group 2 - The case involving Qianhong Pharmaceutical and Dezhan Health reveals that from January 2013 to May 2019, a hospital's pharmacy director received over 116,000 yuan in bribes from various pharmaceutical representatives, including 4,100 yuan from Qianhong Pharmaceutical [5] - The NHSA has established a credit evaluation system for pricing and procurement to address the inflated prices revealed by these cases, aiming to protect patients and healthcare funds [6]

Core Insights - The National Healthcare Security Administration (NHSA) has recently exposed multiple corruption and illegal cases involving various pharmaceutical companies, including Medtronic, Qianhong Pharmaceutical, and Dezhan Health, highlighting systemic issues in the medical procurement process [1][4]. Group 1: Corruption Cases - Medtronic's agents were found to have bribed hospital officials to promote the sale of stents and balloons, with kickbacks of 5,000 RMB per stent and varying amounts for balloons based on their price [2][3]. - The total amount of bribes received by a hospital vice president from Medtronic's agents was reported to be over 6.74 million RMB from 2014 to 2018 [2]. - In a separate case, Qianhong Pharmaceutical and Dezhan Health were implicated in bribery involving hospital procurement officials, with Qianhong's agent providing 41,000 RMB in kickbacks [4]. Group 2: Regulatory Response - The NHSA has established a credit evaluation system for pricing and procurement to address the issues of inflated drug prices and corruption, aiming to protect patients and healthcare funds [5]. - The NHSA plans to guide local healthcare authorities in implementing trust ratings for companies involved in bribery and misconduct, enforcing measures to ensure compliance and safeguard healthcare funds [5].

Core Insights - The company has revised its convertible bond issuance plan to focus on strategic transformation towards innovative drug development [1][2] - The previous acquisition project of Fangyuan Pharmaceutical has been removed due to high uncertainty related to its bankruptcy restructuring [1] - New projects have been added to enhance the focus on innovative drug research, including the III phase clinical study and registration of QHRD211 injection [1] Summary by Sections - **Convertible Bond Issuance Plan**: The company has systematically revised its plan for issuing convertible bonds, emphasizing a strategic shift towards innovative drug development [1][2] - **Project Adjustments**: The original project to acquire 100% of Fangyuan Pharmaceutical has been deleted from the funding plan, while new innovative drug research projects have been strengthened [1] - **Financial Data and Compliance**: The company updated its financial data and disclosure periods to ensure timely and compliant information disclosure, with all related documents revised accordingly [2] - **Management Decision**: The revision of the convertible bond plan reflects a cautious decision by the management to eliminate high-uncertainty projects and concentrate resources on innovative drug development [2]

Group 1 - The core point of the article is that Qianhong Pharmaceutical announced the convening of its sixth board meeting to discuss the agenda for the second extraordinary shareholders' meeting in 2025 [1] - For the first half of 2025, Qianhong Pharmaceutical's revenue composition shows that the biopharmaceutical industry accounts for 99.67%, while other sectors account for 0.33% [1] - As of the report, Qianhong Pharmaceutical has a market capitalization of 10.7 billion yuan [1] Group 2 - The article also mentions that Dapeng Industrial's strategic placement has significantly benefited its insiders, with a subscription price of 9 yuan and a first-day listing price of 118 yuan, resulting in a floating profit of 24.92 million yuan for the controlling shareholder and his brother [1]

股票代码：002550 证券简称：千红制药 常州千红生化制药股份有限公司 Changzhou Qianhong Biopharma Co., Ltd. （常州市新北区云河路 518 号） 向不特定对象发行可转换公司债券 发行方案的论证分析报告 （修订稿） 二〇二五年十一月 1 本报告中如无特别说明，相关用语或简称具有与《常州千红生化制药股份有 限公司向不特定对象发行可转换公司债券预案（修订稿）》中相同的含义。 第一节 本次发行实施的背景 常州千红生化制药股份有限公司（以下简称"千红制药"或"公司"）是在 深圳证券交易所主板上市的公司，为满足公司业务发展的资金需求，增强公司资 本实力，提升盈利能力，根据《公司法》《证券法》《上市公司证券发行注册管理 办法》（以下简称"《注册管理办法》"）等有关法律、法规和规范性文件的规 定，公司拟选择向不特定对象发行可转换公司债券的方式募集资金。 一、医药行业发展空间广阔，市场规模呈增长趋势 中国医药市场由化药、生物药和中药三大板块组成。2024 年中国医药市场 总规模为 16,297.4 亿元，目前中国医药市场中化药占比最大，2024 年其市场规 模为 7,041.4 亿人民 ...